We noted that specialty drug patients often need to adjust their therapy. As people undergo changes in their condition, they may need different doses of their medication, or a new drug entirely. This requires close patient follow-up.
We can get a good illustration of the need for consistent patient follow-up by considering widely used clinical treatment guidelines. In this case we’ll look at some of the guidelines used in treating multiple sclerosis (MS).
Multiple sclerosis is considered an “unpredictable” disease that disrupts the way information moves in the brain, and from the brain and the body. As such, symptoms not only vary from person-to-person, but from day-to-day and year-to-year.10 This high variability makes MS a good candidate for the Review My Care approach.
Adding to the changeable symptoms are the drugs used to treat MS, which are also quite complex. MS is often treated with disease-modifying therapies (DMTs). While not a cure, these drugs are designed to slow or reduce the progress of the disease.11
The decisions around how to treat with DMTs are very complex. Of course, every drug comes with its packet of U.S. Food and Drug Administration (FDA)-approved indications for use. But in addition, there are national and international professional associations that provide physicians with detailed treatment guidelines. There are additional professional groups dedicated just to describing all the factors that govern the use of imaging in the diagnosis of MS.12
One of the key underlying themes of all these recommendations is time. Treatment and imaging of various types should be performed at highly specific points and intervals. For example, imaging should occur when people begin a new drug, after they have used it for a set period, or when they switch to another drug, among many other variables.13
One of the variables to watch for is when a new drug enters the class that may be more suitable for a given patient. This can affect any disease category, but MS in particular has a busy development pipeline. At least 10 new drugs or new indications are in various stages of development and testing right now.14
Any of these MS therapies that can make the jump to FDA approval could potentially trigger a new update to a patient’s treatment.
In light of so many potential opportunities to adjust or change MS treatments, it’s easy to see the problem in having 30% of patients who are not seeing their providers for timely follow-up care.
Special drugs need special programs
Clearly, we need to keep careful tabs on patients who use specialty drugs. And one might ask, aren’t pharmacy benefit managers (PBMs) overseeing patient monitoring as one component of their utilization management (UM) function?
This isn’t the case. Utilization management consists of steps like prior authorization, step therapy and supply limits. These are necessary measures aimed at managing drug access at the beginning of therapy. They help ensure that patients receive the right drug for their condition in the most efficient way.15
But in addition to traditional UM, most PBMs, including Optum Rx, have dedicated specialty clinical programs. However, similar to UM, existing specialty clinical and member engagement services are aimed at members new to treatment. They prioritize assistance in condition management, adherence, answering questions, and educating patients in what to expect from their new treatment.
In contrast, the Review My Care program focuses on treatment-experienced members, and specifically those with a higher likelihood of cost containment opportunities. Review My Care is laser-focused on maximizing specialty pharmacy benefit performance in real time among members who have been on their treatment for longer than 3 months. (Most often patients have been in treatment for 6 to 12 months or longer.)
Care ambassadors
Our world-class data and analytics capabilities are at the heart of Review My Care. Our analytics capabilities enable us to — at the drug level — identify specific opportunities for cost reduction. Examples include adjusting dosing, recommending alternatives that may not have been available when treatment began, or identifying therapeutic duplication or oversupply.
However, health care is more than algorithms. Real people — often facing one of the biggest challenges of their life — need care and attention beyond just drugs.
Therefore, the face of this program is a new role, the care ambassador. We believe that this is the first role of its kind in the specialty pharmacy services and PBM industry.
Optum Rx care ambassadors go beyond traditional member outreach. Care ambassadors are specially trained to consider formulary strategy and benefit design in addition to more customary concerns like clinical safety and efficacy. Their goal is to drive cost savings and enhanced clinical efficacy for both the member and plan sponsor.
In practice, Review My Care care ambassadors conduct specialty drug value assessments with members who demonstrate an opportunity to optimize treatment. Then they help coordinate with prescribers to make changes when clinical and financial considerations warrant.
Program performance is measured through retrospective claims analysis that follows what happened to their specialty drug therapy after the consultation. Examples of successful outcomes include drug discontinuation, dose adjustment, switching to a therapeutic alternative, or switching to a different manufacturer or package size.
Drug value assessments to optimize treatment
Care ambassadors add formulary strategy and benefit design considerations to drive cost savings and clinical efficacy.
